These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10980856)

  • 21. Aggravation of arrhythmia by antiarrhythmic drugs, and the important role of underlying ischemia.
    Podrid PJ; Fogel RI
    Am J Cardiol; 1992 Jul; 70(1):100-2. PubMed ID: 1615848
    [No Abstract]   [Full Text] [Related]  

  • 22. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs.
    Buckingham TA; Bhutto ZR; Telfer EA; Zbilut J
    J Cardiovasc Electrophysiol; 1994 May; 5(5):408-11. PubMed ID: 8055145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and late proarrhythmia from antiarrhythmic drug therapy.
    Morganroth J
    Cardiovasc Drugs Ther; 1992 Feb; 6(1):11-4. PubMed ID: 1533532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
    Slater W; Lampert S; Podrid PJ; Lown B
    Am J Cardiol; 1988 Feb; 61(4):349-53. PubMed ID: 3124591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proarrhythmia.
    Roden DM; Anderson ME
    Handb Exp Pharmacol; 2006; (171):73-97. PubMed ID: 16610341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [QTc-prolonging drugs and the risk of sudden death].
    Reingardiene D; Vilcinskaite J
    Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
    Wolbrette DL
    Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].
    Jaillon P; Simon T
    Therapie; 1992; 47(3):187-92. PubMed ID: 1295119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Proarrhythmic effects of anti-arrhythmia agents].
    Scanu P; Agostini D; Grollier G; Belin A; Valette B; Potier JC
    Rev Med Interne; 1995; 16(8):602-7. PubMed ID: 7569432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist.
    Thibault B; Nattel S
    J Cardiovasc Electrophysiol; 1999 Mar; 10(3):472-81. PubMed ID: 10210515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Torsades de pointes and proarrhythmia.
    Ben-David J; Zipes DP
    Lancet; 1993 Jun; 341(8860):1578-82. PubMed ID: 8099651
    [No Abstract]   [Full Text] [Related]  

  • 34. [Arrhythmias and heart failure].
    Amann FW; Candinas R
    Ther Umsch; 1993 Jun; 50(6):419-24. PubMed ID: 8351673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arrhythmogenic effects of anti-arrhythmia agents].
    Pfeiffer D; Rostock KJ; Rathgen K; Schirdewan A; Kleiner HJ
    Z Gesamte Inn Med; 1987 Jul; 42(14):390-4. PubMed ID: 3673134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia.
    Packer M; Gottlieb SS; Kessler PD
    Am J Med; 1986 Apr; 80(4A):23-9. PubMed ID: 2871753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should asymptomatic ventricular arrhythmias in patients with congestive heart failure be treated with antiarrhythmic drugs?
    Francis GS
    J Am Coll Cardiol; 1988 Jul; 12(1):274-83. PubMed ID: 3288678
    [No Abstract]   [Full Text] [Related]  

  • 40. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
    Nagra BS; Ledley GS; Kantharia BK
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.